Available Clinical Trials

Clinical Trials

Cancer Type or Disease

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355). E-mail: askroswell@roswellpark.org

Roswell Park Neuroendocrine Tumor Biobank

Principal Investigator: Iyer, Renuka V

(S1706) A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer

Principal Investigator: Fung-Kee-Fung, Simon

Art in the Workplace

Principal Investigator: Guru, Khurshid

(A021602) RANDOMIZED, DOUBLE-BLINDED PHASE III STUDY OF CABOZANTINIB VERSUS PLACEBO IN PATIENTS WITH ADVANCED NEUROENDOCRINE TUMORS AFTER PROGRESSION ON EVEROLIMUS (CABINET)

Principal Investigator: Iyer, Renuka V

(I5B-MC-JGDP(c)):A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer

Principal Investigator: Fountzilas, Christos

(A061202) A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib Vs. Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Relapsing on Lenalidomide as Part of First Line Therapy

Principal Investigator: Hillengass, Jens

Flavored Tobacco Product Regulation: Behavioral Economic Demand, Visual Attention, and Flavored Tobacco Product Availability

Principal Investigator: Quisenberry, Amanda J

Effects of filter ventilation on sensory response, smoking topography, and inhalation (COMET 2 2.1)

Principal Investigator: O'Connor, Richard J

(ACCL1633) The Effectiveness of Lactobacillus plantarum in Preventing Acute Graft-versus-Host Disease (GvHD) in Children undergoing Alternative Hematopoietic Progenitor Cell Transplantation (HCT)

Principal Investigator: Bambach, Barbara J

(COG AHEP1531) Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)

Principal Investigator: Twist, Clare J

Enhancing Relapse Prevention with rTMS: Dose-Response Parameters for Smoking Cessation

Principal Investigator: Sheffer, Christine E

Changes in respiratory symptoms and inflammation markers among e-cigarette users during spontaneous "switching" between flavors (CRoFT_3.1)

Principal Investigator: Goniewicz, Maciej L

Exercise and Nutrition Intervention in Older Breast Cancer Survivors- The WIN CA Study

Principal Investigator: O'Connor, Tracey L

Effects of Physical Distraction and Music on Anxiety during Mohs Surgery

Principal Investigator: Schierer, Shirley

(EA5162) Phase II Study of AZD9291 (Osimertinib) in Advanced NSCLC Patients with Exon 20 Insertion Mutations in EGFR

Principal Investigator: Dy, Grace K

(S1602) A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-Naïve High-Grade Non-Muscle Invasive Bladder Cancer

Principal Investigator: Li, Qiang J

A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial of Adjuvant Avelumab (Anti-PDL-1 antibody) in Merkel Cell Carcinoma Patients with Clinically Detected Lymph Node Metastases (Adjuvant Avelumab in MCC (ADAM) Trial

Principal Investigator: Ernstoff, Marc S

(B1371012) AN OPEN-LABEL PHASE 1B STUDY OF PF-04449913 (GLASDEGIB) IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH PREVIOUSLY UNTREATED HIGHER-RISK MYELODYSPLASTIC SYNDROME, ACUTE MYELOID LEUKEMIA, OR CHRONIC MYELOMONOCYTIC LEUKEMIA

Principal Investigator: Wang, Eunice S

Understanding the relationship of caregiver stress to perceived preparedness for prescribed tasks and responsibilities caring for patients undergoing Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy (CS+HIPEC)

Principal Investigator: Stewart, Erika S

Photoacoustic Imaging of Human Breast

Principal Investigator: Bonaccio, Ermelinda

MATCH Treatment Subprotocol Z1F: Phase II Study of Copanlisib in Patients with Tumors with PIK3CA Mutations (PTEN Loss Allowed)

Principal Investigator: Levine, Ellis G

(ANBL1531) A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma

Principal Investigator: Twist, Clare J

MATCH Treatment Subprotocol K2: Phase 2 Study of JNJ-42756493 (erdafitinib) in Patients with Tumors with FGFR Mutations or Fusions

Principal Investigator: Levine, Ellis G

MATCH Treatment Subprotocol K1: Phase 2 Study of JNJ-42756493 (Erdafitinib) in Patients with Tumors with FGFR Amplifications

Principal Investigator: Levine, Ellis G

A Phase 1/2a Study of BMS-986179 Administered Alone and in Combination with Nivolumab (BMS-936558) in Subjects with Advanced Solid Tumors (CA013-004)

Principal Investigator: Ernstoff, Marc S

(NRG-GY007) A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Principal Investigator: Lele, Shashikant B

Evaluation of Roswell Park Cessation Services

Principal Investigator: Sheffer, Christine E

ProSTAR: A Phase 1b/2 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, Combined with Enzalutamide or Abiraterone/Prednisone in Patients with Metastatic Castration Resistant Prostate Cancer

Principal Investigator: Chatta, Gurkamal S

Strengthening knowledge for future generations: Cancer bio-banks in the landscapes of the Haudenosaunee

Principal Investigator: Haring, Rodney C

Evaluation of Burnout and Wellness Among Gynecologic Oncology Fellows Nationwide

Principal Investigator: Zsiros, Emese

A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20)

Principal Investigator: Dy, Grace K

Problem Solving Skills Training in Adult Cancer Survivors: Bright IDEAS-AC

Principal Investigator: Noyes, Ekaterina

Understanding health behaviors and perceptions of cancer in non-English speaking populations

Principal Investigator: Glaser, Kathryn M

(BL-8040.AML.202) A Phase Ib/II, Multicenter, Single Arm, Open-Label Study, To Evaluate the Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab Combination for Maintenance Treatment in Subjects with Acute Myeloid Leukemia who are 60 Years...

Principal Investigator: Wang, Eunice S

(UTX-TGR-205) A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin's Lymphoma

Principal Investigator: Hernandez-Ilizaliturri, Francisco J

Phase 2, Multi-Arm Study of Niraparib Administered Alone and in Combination with Pembrolizumab in Patients with Non-Small Cell Lung Cancer

Principal Investigator: Dy, Grace K

(ARO-013) Phase III Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy of the Addition of Crenolanib to Salvage Chemotherapy Versus Salvage Chemotherapy Alone in Subjects ≤ 75 Years of Age with Relapsed/Refractory FLT3...

Principal Investigator: Wang, Eunice S

General Anesthetics in CAncer REsection Surgery (GA-CARES) Trial: Pragmatic Randomized Trial of Propofol vs Volatile Inhalational Anesthesia

Principal Investigator: Quinn, Timothy D

A Randomized, Open-Label Study to Assess the Pain, Toxicity and Quality of Life Effects of Adding Venlafaxine to the Pain Management Regimen for Patients Treated with Chemoradiation for Head and Neck Cancer

Principal Investigator: Singh, Anurag K

(ATLAS CO-338-085) A Phase 2, Open-label Study of Rucaparib in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

Principal Investigator: Chatta, Gurkamal S

Clinical Trial and Enrollment & Oncology Pathways

Principal Investigator: McKinney-Bost, Mishellene R

OSCO-P1301 A Phase 1 Dose Escalation Trial of SKI-G-801 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Principal Investigator: Wang, Eunice S

(H125001) An Open-Label Phase 1 / 2 Study of JCARH125, BCMA targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects with Relapsed and/or Refractory Multiple Myeloma

Principal Investigator: Lee, Kelvin

(ARO-021) Phase III Randomized Study of Crenolanib versus Midostaurin Administered Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects with FLT3 Mutated Acute Myeloid Leukemia

Principal Investigator: Wang, Eunice S

First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of Axl-specific antibody-drug conjugate (HuMax-AXL-ADC) in patients with solid tumors.

Principal Investigator: Dy, Grace K

Clinical Proteomics Tumor Analysis Consortium (CPTAC) Phase III Research Protocol

Principal Investigator: Foster, Barbara A

A prospective international multicenter phase II study to evaluate the efficacy, safety and quality of life of oral daily pazopanib in patients with advanced and/or metastatic renal cell carcinoma after previous therapy with checkpoint inhibitor treatment

Principal Investigator: George, Saby

(0801) A Phase 1, Multi-center, Open-label Study of IMGN632 Administered Intravenously in Patients with Relapsed/Refractory CD123-positive Acute Myeloid Leukemia and Other CD123-positive Hematologic Malignancies

Principal Investigator: Wang, Eunice S

Effects of package color and descriptors on tobacco product perceptions (COMET 2 1.2)

Principal Investigator: O'Connor, Richard J

A Pilot Study of Photoacoustic Imaging (PAI)

Principal Investigator: Singh, Anurag K

Identifying circadian-regulated radiosensitive markers in healthy volunteers an initial step for personalized chrono-therapy in cancer treatment

Principal Investigator: Gu, Fangyi

(NSABP B-51) A Randomized Phase III Clinical Trial Evauluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to...

Principal Investigator: Fung-Kee-Fung, Simon

RE-AIMing Nurses for Sleep Screening, Brief Intervention and Referral to Treatment (Sleep-SBIRT)

Principal Investigator: Dean, Grace E

Isolation of CD34 stem cells using the Miltenyi Biotec CliniMACS CD34 Reagent System as a humanitarian use device

Principal Investigator: Chen, George L

AALL1631 International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbones

Principal Investigator: Twist, Clare J

(IRB17-0578) Phase I study of stereotactic body radiotherapy (SBRT) followed by nivolumab or ipilimumab with nivolumab in unresectable hepatocellular carcinoma

Principal Investigator: Iyer, Renuka V

(NRG-GI004/SWOG-S1610) Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevaczumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment...

Principal Investigator: Boland, Patrick M

Spatial Analysis of Bladder Cancer in Western New York

Principal Investigator: Guru, Khurshid

(A221504) A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PILOT STUDY OF AN ORAL, SELECTIVE PERIPHERAL OPIOID RECEPTOR ANTAGONIST IN ADVANCED NON-SMALL CELL LUNG CANCER (ADENOCARCINOMA)

Principal Investigator: Chen, Hongbin

Opioid Use in Post-operative Gynecologic Oncology Patients

Principal Investigator: Zsiros, Emese

(BGB-A317/BGB-290_Study_001) A Phase 1/1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activity of the anti-PD-1 Monoclonal Antibody BGB-A317 in combination with the PARP...

Principal Investigator: Fountzilas, Christos

A MULTICENTER, OPEN-LABEL, PHASE 1B/2 STUDY TO EVALUATE SAFETY AND EFFICACY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH CHEMOTHERAPY WITH OR WITHOUT OTHER ANTI-CANCER IMMUNOTHERAPIES AS FIRST-LINE TREATMENT IN PATIENTS WITH ADVANCED MALIGNANCIES

Principal Investigator: George, Saby

ASTX727-02: A Phase 3, Randomized, Open-Label Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) versus IV Decitabine in Subjects with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Principal Investigator: Griffiths, Elizabeth A

(ADP-0000-001) A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects with Solid or...

Principal Investigator: Odunsi, Adekunle O

(ACCRU-GI-1617) MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer

Principal Investigator: Boland, Patrick M

(SGN22E-002) A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer

Principal Investigator: George, Saby

(SWOG S1616) A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) OR Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD-1 or Anti-PD-L1 Agent

Principal Investigator: Puzanov, Igor

A Phase 2, Randomized, Biomarker-driven, Clinical Study in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with an Exploratory Arm in Patients with Newly Diagnosed High-Risk AML and Exploratory Arms with Varying Levels of MCL-1...

Principal Investigator: Wang, Eunice S

A Phase II Neoadjuvant Study of Palbociclib in Combination with Letrozole and Trastuzumab as Neoadjuvant Treatment of Stage II-III ER+ HER2+ Breast Cancer (PALTAN)

Principal Investigator: Levine, Ellis G

The GYN Molecular Information Registry

Principal Investigator: Odunsi, Adekunle O

(A031501) Phase III Randomized Adjuvant study of MK-3475 (pembrolizumab) in muScle invaSive and locally ADvanced urOthelial caRcinoma (AMBASSADOR) versus observation

Principal Investigator: Levine, Ellis G

(A021502) Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch

Principal Investigator: Boland, Patrick M

NCI 10057: A Phase II Study of talimogene laherparepvec (T-VEC) Followed by talimogene laherparepvec (T-VEC) + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors

Principal Investigator: Puzanov, Igor

BMT CTN 1506; A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML

Principal Investigator: Balderman, Sophia R

(A041501) A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL

Principal Investigator: Wang, Eunice S

(ONO-7475-01) A Phase I open label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary clinical efficacy of ONO-7475 in patients with acute leukemias

Principal Investigator: Wang, Eunice S

(ALTE1631) A Randomized Web-Based Physical Activity Intervention Among Children and Adolescents with Acute Lymphoblastic Leukemia

Principal Investigator: Rokitka, Denise A

C-144-01: A Phase 2, Multicenter Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Treatment of Patients with Metastatic Melanoma

Principal Investigator: Ernstoff, Marc S

(APEC1621SC) NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE) SCREENING PROTOCOL

Principal Investigator: Twist, Clare J

Electronic Cigarette Use During Pregnancy

Principal Investigator: Goniewicz, Maciej L

ALTE 15N2 LEAHRN (Late Effects After High-Risk Neuroblastoma) Study

Principal Investigator: Rokitka, Denise A

Phase II Study of Targeting CD28 in Multiple Myeloma with Abatacept (CTLA4-Ig) to Overcome Resistance to Chemotherapy

Principal Investigator: Lee, Kelvin

A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, in Patients with Advanced Solid Malignancies and Lymphoma with an Expansion in Select Malignancies (RGX-104-001)

Principal Investigator: Puzanov, Igor

(APEC1621) NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)

Principal Investigator: Twist, Clare J

ACNS 1422 A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients

Principal Investigator: Twist, Clare J

A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer

Principal Investigator: Chatta, Gurkamal S

Validation of a mobile imaging system for oral cancer screening in low resource settings in India

Principal Investigator: Singh, Anurag K

(BMT CTN Protocol 1507) Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease

Principal Investigator: Balderman, Sophia R

Phase 2a Study Evaluating a Chemokine-Modulatory Regimen in Patients with Colorectal Cancer Metastatic to the Liver

Principal Investigator: Boland, Patrick M

(CA209-812) Randomized, Open-label, Phase 3 Trial of Nivolumab plus Brentuximab vedotin versus Brentuximab vedotin alone in Participants with Relapsed Refractory or Ineligible for Autologous Stem Cell Transplant (ASCT) Advanced Stage Classical Hodgkin...

Principal Investigator: Torka, Pallawi

A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (anit-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (anti-PD-1 mAb) in Patients with...

Principal Investigator: Dy, Grace K

(NRG-GY006) A Randomized phase II trial of radiation therapy and cisplatin alone or in combination with intravenous triapine in women with newly diagnosed bulky stage IB2, or stage II, IIIB, or IVA cancer of the uterine cervix or stage II-IVA vaginal...

Principal Investigator: Lele, Shashikant B

(PCYC-1141-CA) A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve...

Principal Investigator: Hernandez-Ilizaliturri, Francisco J

A Phase Ib/II Study of Propranolol with Fixed-dose Pembrolizumab in Patients with Unresectable Stage III and Stage IV Melanoma

Principal Investigator: Gandhi, Shipra

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Principal Investigator: Wang, Eunice S

A Phase 1/2, Multicenter, Open-Label, Study of FT 2102 as a Single Agent and in Combination with Azacitidine or Cytarabine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 Mutation

Principal Investigator: Wang, Eunice S

COG AGCT1531 A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors

Principal Investigator: Twist, Clare J

RCT of Online Mindfulness-Based Stress Reduction for Metastatic Breast Cancer Patients

Principal Investigator: Hydeman, Jennifer A

The effect of extra-physiologic oxygen shock / stress (EPHOSS) on human hematopoietic stem cell viability and multi-potency

Principal Investigator: Chen, George L

A Phase III, Randomized, Double-Blind, Clinical Trial of Pembrolizumab (MK-3475) plus Chemotherapy (XP or FP) versus Placebo plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects with Gastric and Gastroesophageal Junction (GEJ)...

Principal Investigator: Fountzilas, Christos

AG120-C-009 A Phase 3, Multicenter, Double-Blind, Randomized, Placebo Controlled Study of AG-120 in Combination with Azacitidine in Subjects = 18 Years of Age with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation

Principal Investigator: Wang, Eunice S

A Phase 1-2, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors (PROCLAIM-CX...

Principal Investigator: Opyrchal, Mateusz

PHASE 1/2 STUDY OF TAS-120 IN PATIENTS WITH ADVANCED SOLID TUMORS HARBORING FGF/FGFR ABERRATIONS

Principal Investigator: Iyer, Renuka V

A Phase 1 Study of DEC205mAb-NY ESO 1 Fusion Protein (CDX-1401) given with Adjuvant Poly-ICLC in Conjunction with 5-Aza-2'deoxycytidine (Decitabine) and Nivolumab in Patients with MDS or Low Blast Count AML

Principal Investigator: Griffiths, Elizabeth A

An Open-Label, Single-Arm, Phase 2 Study of AVB-620 in Women with Primary Nonrecurrent Breast Cancer Undergoing Surgery

Principal Investigator: Takabe, Kazuaki

A phase 3, multi-center open-label randomized study of oral ABL001 versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors

Principal Investigator: Thompson, J E

A PHASE II TRIAL OF HAPLOIDENTICAL ALLOGENEIC STEM CELL TRANSPLANTATION UTILIZING MOBILIZED PERIPHERAL BLOOD STEM CELLS.

Principal Investigator: Balderman, Sophia R

Three Pilot Studies of Stereotactic Body Radiation Therapy (SBRT) and Surgery in Non-Small Cell Lung Cancer

Principal Investigator: Singh, Anurag K

Alteration of Serum Cytokines During ADT in Treatment-Naive Prostate Cancer Patients

Principal Investigator: Nastiuk, Kent L

PISCES OMS I-103: A Multicenter Phase 2, Open-Label Study of Intratumoral Tavokinogene Telseplasmid (tavo, pIL-12) plus Electroporation in Combination with Intravenous Pembrolizumab in Patients with Stage III/IV Melanoma who are Progressing on either...

Principal Investigator: Puzanov, Igor

Pilot Study: Assess the Impact on Patient Experience With Curbell's Rego Patient Interactive Device

Principal Investigator: De Wald, Renee L

Phase 2 Study of TAK-659 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma After at Least 2 Prior Lines Of Chemotherapy

Principal Investigator: Torka, Pallawi

CA-ALT-803-01-16, QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination with ALT-803 in Patients with BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

Principal Investigator: Guru, Khurshid

Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomization Trial

Principal Investigator: Levine, Ellis G

IRONMAN: International Registry for Men with Advanced Prostate

Principal Investigator: Chatta, Gurkamal S

A Phase 3 Randomized Study Comparing Nivolumab and Ipilimumab Combination vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse

Principal Investigator: George, Saby

IMCgp100-202, A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigator's Choice in HLA-A*0201 Positive Patients with Previously Untreated Advanced Uveal Melanoma

Principal Investigator: Puzanov, Igor

A Pilot Study of Photoacoustic Imaging (PAI) in H&N Cancer Patients

Principal Investigator: Singh, Anurag K

A Phase Ib/II Trial of Interleukin-2 in Combination with Pembrolizumab for Patients with Unresectable or Metastatic Melanoma

Principal Investigator: Puzanov, Igor

(ASTX660-01) Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas

Principal Investigator: Hernandez-Ilizaliturri, Francisco J

Impact of Menthol Delivery Methods on Smoker Sensory Perceptions

Principal Investigator: O'Connor, Richard J

A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab (MK-3475) in Combination with Cisplatin and 5-Fluorouracil versus Placebo in Combination with Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects with...

Principal Investigator: Fountzilas, Christos

Race and geographic differences in diagnosis with metastatic Prostate cancer and early detection

Principal Investigator: Sumlin, Adam B

TRITON3:A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physicians Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency

Principal Investigator: Chatta, Gurkamal S

TISSUE AND DATA ACQUISITION ACTIVITY FOR THE STUDY OF GYNECOLOGIC DISEASE

Principal Investigator: Odunsi, Adekunle O

A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC).

Principal Investigator: Boland, Patrick M

MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene Expression Profiles: An Adaptable Registry (FLEX Registry)

Principal Investigator: Levine, Ellis G

(S1605) Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Principal Investigator: Li, Qiang J

105SAR301, A RANDOMIZED PHASE 3 TRIAL OF TRC105 AND PAZOPANIB VERSUS PAZOPANIB ALONE IN PATIENTS WITH ADVANCED ANGIOSARCOMA (TAPPAS);

Principal Investigator: Grand'Maison, Anne C

NRG-BR005: A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response after Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving...

Principal Investigator: Levine, Ellis G

2125-204, A Phase 1/2 Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination with Ipilimumab or Pembrolizumab in Patients with Metastatic Melanoma

Principal Investigator: Puzanov, Igor

DFCI ALL Consortium 16-001: Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents

Principal Investigator: Kelly, Kara M

A Phase 1/2 dose escalation study with expansion cohorts to investigate the safety, biologic and anti-tumor activity of ONCOS-102 in combination with durvalumab in subjects with advanced peritoneal malignancies

Principal Investigator: Odunsi, Adekunle O

AHOD1721, Risk-based, response-adapted, Phase II open-label trial of nivolumab + brentuximab vedotin(N + Bv) for children, adolescents, and young adults with relapsed/refractory (R/R) CD30 +classic Hodgkin lymphoma (cHL) after failure of first-line...

Principal Investigator: Kelly, Kara M

Life On The Go 2: Evaluating the Effect of Physical Activity of Patients with Recurrent Ovarian Cancer Using State of the Art Activity Tracking Device

Principal Investigator: Zsiros, Emese

SL-401 in Patients with Advanced, High Risk Myeloproliferative Neoplasms

Principal Investigator: Wang, Eunice S

(NCI 9930) A Phase I Trial of MEDI-570 in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)

Principal Investigator: Hernandez-Ilizaliturri, Francisco J

Implementing a Low Glycemic Diet in Children and Adolescents Undergoing Treatment for Acute Lymphoblastic Leukemia

Principal Investigator: Kelly, Kara M

A Pilot Study of Feasibility of Performing Intravital Microscopy in Patients with Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Principal Investigator: Odunsi, Adekunle O

(S1609) DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors

Principal Investigator: Puzanov, Igor

A Phase Ib/2 Trial of Fludarabine/Melphalan/Total Body Irradiation with Post Transplant Cyclophosphamide as Graft versus Host Disease Prophylaxis in Matched-Related and Matched-Unrelated Allogeneic Hematopoietic Cell Transplantation

Principal Investigator: Ho, Christine M

Talking Pictures: An exploratory study of meaning-based social media intervention for Adolescent and Young Adult cancer patients

Principal Investigator: Pailler, Megan E

Art Heals

Principal Investigator: Guru, Khurshid

A Phase Ib/ II Study of Sorafenib and Pembrolizumab in Advanced Hepatocellular Cancer (HCC)

Principal Investigator: Iyer, Renuka V

A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

Principal Investigator: Mohler, James L

(NRG-GU002) Phase II-III Trial Of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or without Adjuvant Docetaxel

Principal Investigator: Chatta, Gurkamal S

Exercise to Improve Health and Quality-of-life in Breast Cancer Survivors

Principal Investigator: O'Connor, Tracey L

YO39523 / GOG-3015: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR...

Principal Investigator: Lele, Shashikant B

A Phase 1b Study of Intratumoral IMO 2125 in Patients with Refractory Solid Tumors (2125-RST-101)

Principal Investigator: Puzanov, Igor

(RTOG 1119) Phase II Randomized Study of Whole Brain Radiotherapy/Stereotactic Radiosurgery in Combination with Concurrent Lapatinib in Patients with Brain Metastasis From HER2-Positive Breast Cancer - A Collaboartive Study of NRG Oncology and KROG

Principal Investigator: Prasad, Dheerendra

Direct oral anticoagulants (DOACs) versus LMWH +/- warfarin for VTE in cancer: A randomized effectiveness trial (CANVAS trial)

Principal Investigator: Levine, Ellis G

BMT CTN 1502 Optimizing Haploidentical Aplastic Anemia Transplantation (CHAMP)

Principal Investigator: Bambach, Barbara J

A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency

Principal Investigator: Chatta, Gurkamal S

A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants with Advanced Renal Cell Carcinoma (FRACTION-RCC)

Principal Investigator: George, Saby

A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

Principal Investigator: George, Saby

A Multicenter Pivotal Phase 3 study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Older Subjects with Active, Relapsed, or Refractory Acute Myeloid Leukemia

Principal Investigator: Chen, George L

An Open-Label Phase 1/2 Study of INCB039110 in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Principal Investigator: Torka, Pallawi

An Open-label, Multicenter Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia

Principal Investigator: Wang, Eunice S

MATCH Treatment Subprotocol M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations

Principal Investigator: Levine, Ellis G

MATCH Treatment Subprotocol L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations

Principal Investigator: Levine, Ellis G

A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion- Positive Tumors (LOXO-TRK-15002).

Principal Investigator: Grand'Maison, Anne C

A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies

Principal Investigator: Chatta, Gurkamal S

INCB 18424-269 (COG AALL1521) A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway Mutant Acute Lymphoblastic Leukemia

Principal Investigator: Twist, Clare J

A multicenter open-label treatment protocol of gilteritinib (ASP2215) in patients with FMS-like tyrosine kinase 3 (FLT3) mutated relapsed or refractory acute myeloid leukemia (AML) or FLT3 mutated AML in complete remission (CR) with minimal residual...

Principal Investigator: Wang, Eunice S

A Phase 2/3 Multicenter, Open-label, 3 arm, 2 stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not...

Principal Investigator: Wang, Eunice S

MATCH Treatment Subprotocol Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions

Principal Investigator: Levine, Ellis G

(EAQ152): COMET - Communication and Education in Tumor Profiling:A Randomized Study of Pre-disclosure Genetic Education v Usual Care in Tumor Profiling for Advanced Cancer and a Pilot Study of Remote Genetic Counseling for Participants with Potential...

Principal Investigator: Levine, Ellis G

(S1512) A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unresectable Desmoplastic Melanoma (DM)

Principal Investigator: Ernstoff, Marc S

A PHASE 1 STUDY OF ES414 IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Principal Investigator: Chatta, Gurkamal S

S1418/BR006) A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 [Pembrolizumab] as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After...

Principal Investigator: Levine, Ellis G

( SCRX001-006) An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors

Principal Investigator: Dy, Grace K

Vigilant Observation of Gliadel Wafer Implant (VIGILANT) Registry: A multicenter, observational registry to collect information on the safety and effectiveness of Gliadel Wafer (Carmustine Implant) used in usual medical practice

Principal Investigator: Fabiano, Andrew J

A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Subjects with Advanced Non-small Cell Lung Cancer (FRACTION-Lung)

Principal Investigator: Dy, Grace K

A Phase 1/2, Open-label, Multicenter Study of the Combination of NKTR-214 and Nivolumab or the Combination of NKTR-214, Nivolumab, and Ipilimumab in Patients with Select Locally Advanced or Metastatic Solid Tumor Malignancies

Principal Investigator: Puzanov, Igor

A phase 1/2 Study of in situ vaccination with tremelimumab and IV durvalumab plus the Toll-like receptor agonist PolyICLC in Subjects with Advanced, Measurable, Biopsy-accessible Cancers

Principal Investigator: Opyrchal, Mateusz

(A011502): A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial

Principal Investigator: Levine, Ellis G

(COG ANHL12P1) A Randomized Phase II Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC# 749005, Commerically Labeled) in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL) IND# 117117

Principal Investigator: Barth, Matthew J

Randomized phase IB/II study of enzalutamide with and without ribociclib in patients with metastatic castrate resistant, chemotherapy naïve prostate cancer that retains RB expression

Principal Investigator: Chatta, Gurkamal S

A multinational, open-label, dose escalation Phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumor types

Principal Investigator: Odunsi, Adekunle O

A Phase 1 Dose-Escalation and Cohort-Expansion Study of Intravenous CBL0137 in Subjects with Previously Treated Hematological Cancers

Principal Investigator: Hernandez-Ilizaliturri, Francisco J

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Principal Investigator: Griffiths, Elizabeth A

S1416, Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer with or Without Metastases

Principal Investigator: Levine, Ellis G

A011401; Randomized Phase III Trial Evaluating The Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

Principal Investigator: O'Connor, Tracey L

A221208; Randomized Phase II Study: Corticosteroids + Bevacizumab VS. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases

Principal Investigator: Prasad, Dheerendra

(CITN-12) Phase I Study of MK-3475 (Pembrolizumab) in Patients with Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm

Principal Investigator: Ernstoff, Marc S

A Phase I Open Label Clinical Trial Evaluating the Safety and Efficacy of Adoptive Transfer of NY-ESO-1 TCR Engineered Autologous T Cells in Combination with Decitabine in Patients with Recurrent or Treatment Refractory Ovarian Cancer

Principal Investigator: Odunsi, Adekunle O

MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion

Principal Investigator: Levine, Ellis G

A Phase I/II Basket Trial of the EGF Vaccine CIMAvax in Combination with the Anti-PD1 Therapy in Patients with Advanced NSCLC or Squamous Head and Neck Cancer

Principal Investigator: Dy, Grace K

Double-arm, Randomized Study of Botulinum Toxin Injection as a Pyloric Drainage Procedure for Minimally Invasive Esophagectomy (Phase II)

Principal Investigator: Kukar, Moshim

A Phase I Evaluation of Olaparib in combination with Durvalumab and Tremelimumab in the Treatment of Recurrent Platinum Sensitive or Resistant or Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Patients who Carry a...

Principal Investigator: Odunsi, Adekunle O

A Phase I/II Open-Label Study of Nimotuzumab in Combination with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer

Principal Investigator: Dy, Grace K

A Phase 1 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combinationwith Pembrolizumab in Subjects with Advanced Solid Tumors

Principal Investigator: Ernstoff, Marc S

(EA5142) Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

Principal Investigator: Dy, Grace K

A Phase 1, Multi-Center, Open-Label Study of IMGN779 Administered Intravenously in Adult Patients with Relapsed/Refractory CD33-Positive Acute Myeloid Leukemia

Principal Investigator: Wang, Eunice S

(COG ALTE1621) Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial

Principal Investigator: Rokitka, Denise A

A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects With Advanced Malignancies

Principal Investigator: Wang, Eunice S

(EAY 131-V MATCH): Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)

Principal Investigator: Levine, Ellis G

(EAY 131-T MATCH): GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations

Principal Investigator: Levine, Ellis G

EAY 131-S2 MATCH): Phase II Study of Trametinib in Patients with Tumors with GNAQ or GNA11 mutations

Principal Investigator: Levine, Ellis G

(EAY 131-E MATCH): AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR

Principal Investigator: Levine, Ellis G

(EAY 131-G MATCH): Phase II Study of Crizotinib in Patients with ROS1 Translocations (Other Than Patients with Non-Small Cell Lung Cancer)

Principal Investigator: Levine, Ellis G

(EAY 131-F MATCH): Crizotinib in Patients with Tumors (Other Than Adenocarcinoma of Lung or ALCL) with ALK Translocations

Principal Investigator: Levine, Ellis G

(EAY 131-A MATCH): Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment

Principal Investigator: Levine, Ellis G

(EAY 131 Master Protocol) Molecular Analysis for Therapy Choice (MATCH)

Principal Investigator: Levine, Ellis G

Phase 0 Trial of Presurgical Cholesterol-lowering on Prostate Cancer Cell Growth

Principal Investigator: Mohler, James L

Phase IB/II Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination with Polatuzumab Vedotin and Venetoclax in Patients with Relapsed or Refractory Follicular Lymphoma and Rituximab in combination with polatuzumab vedotin and...

Principal Investigator: Hernandez-Ilizaliturri, Francisco J

A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

Principal Investigator: George, Saby

A Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Principal Investigator: Lee, Kelvin

(EA1131) A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Principal Investigator: Levine, Ellis G

(COG APEC14B1) The Project: Everychild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study

Principal Investigator: Twist, Clare J

A Phase Ib/II Study of Cetuximab and Pembrolizumab in Metastatic Colorectal Cancer

Principal Investigator: Boland, Patrick M

(12-100) Phase I/II Trial of Pre-Operative Image Guided Intensity Modulated Proton Radiation Therapy (IMPT) or Photon (IMRT) with Simutaneously Integrated Boost to the High Risk Margin for Retroperitoneal Sarcomas

Principal Investigator: Kane, John M

(A031102) A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Pacilitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide ...

Principal Investigator: Levine, Ellis G

A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

Principal Investigator: Levine, Ellis G

A Dose Regimen-Finding Study to Evaluate the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetics, and Activity of Oraxol in Subjects with Advanced Malignancies

Principal Investigator: Opyrchal, Mateusz

(ACCL1333/CV185-155) A Phase III Randomized, Open Label, Multi-center Study of the Safety and Efficacy of Apixaban for Thromboembolism Prevention versus No Systemic Anticoagulant Prophylaxis during Induction Chemotherapy in Children with Newly...

Principal Investigator: Bambach, Barbara J

(COG AAML1331) A Phase III Study For Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid

Principal Investigator: Twist, Clare J

A Phase 1b/2, Open-label, Dose Escalation Study of Entinostat in Combination with Pembrolizumab in Patients with Non-small Cell Lung Cancer, with Expansion Cohorts in Patients with Non-small Cell Lung Cancer, Melanoma, and Mismatch Repair-Proficient...

Principal Investigator: Opyrchal, Mateusz

(COG AALL1331) Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC# 765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)

Principal Investigator: Twist, Clare J

A Phase II, Multicenter, Study of Oral cMET Inhibitor INC280 in Adult Patients with EGFR Wild-Type (wt), Advanced Non-Small Cell Lung Cancer (NSCLC)

Principal Investigator: Chen, Hongbin

(COG ANBL1232) Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma

Principal Investigator: Higman, Meghan

(COG AHOD1331) A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults

Principal Investigator: Higman, Meghan

SL-401 in Patients with Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm

Principal Investigator: Wang, Eunice S

(S1400) A Biomarker-Driven Master Protocol for Previously treated Squamous Cell Lung Cancer (Lung-Map)

Principal Investigator: Chen, Hongbin

Phase II Randomized, Double-Blind, Placebo-Controlled Study Evaluating Nintedanib Versus Placebo as Prophylaxis against Radiation Pneumonitis in Patients with Unresectable NSCLC Undergoing Chemoradiation Therapy

Principal Investigator: Dy, Grace K

(E4512 )A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Principal Investigator: Chen, Hongbin

(A081105) Randomized Study of Erlotinib or Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

Principal Investigator: Dy, Grace K

(A151216) Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Principal Investigator: Dy, Grace K

A Phase I/IIa Study of TGFß Blockade in TCR-Engineered T-Cell Cancer Immunotherapy in Patients with Advanced Malignancies

Principal Investigator: Odunsi, Adekunle O

(E1910) A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults

Principal Investigator: Wang, Eunice S

A Dose-Regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects with Advanced Malignancies

Principal Investigator: Boland, Patrick M

A Phase I Study of Ceritinib (LDK378), a Novel ALK Inhibitor, in Combination with Gemcitabine-Based Chemotherapy in Patients with Advanced Solid Tumors

Principal Investigator: Iyer, Renuka V

Detection of Early Lung Cancer Among Military Personnel Study 2 (DECAMP-2): Screening of Patients at High Risk for Developing Lung Cancer with a Civilian Expansion

Principal Investigator: Reid, Mary E

A Phase I/IIb Study of DEC205mAb-NY-ESO-1 Fusion Protein (CDX-1401) Given with Adjuvant Poly-ICLC in Combination with INCB024360 for Patients in Remission with Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Whose Tumors Express NY...

Principal Investigator: Odunsi, Adekunle O

(A011202) A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 NI) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

Principal Investigator: Levine, Ellis G

(COG ALTE11C2) Health Effects After Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-Related Cardiomyopathy

Principal Investigator: Rokitka, Denise A

Reduced Burden of Oncologic Therapy in Advanced B-cell Lymphoma (REBOOT ABLY) in Children, Adolescents and Young Adults with CD20+ Mature B-Cell Lymphoma

Principal Investigator: Barth, Matthew J

Phase I/II Study of Carfilzomib plus Rituximab plus Ifosfamide plus Carboplatin plus Etoposide (C-R-ICE) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Principal Investigator: Hernandez-Ilizaliturri, Francisco J

N1048 PROSPECT**) A Phase II/III Trial of Neoadjuvant FOLFOX with Selective Use of Combined Modality Chemoradiaiton Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with...

Principal Investigator: Nurkin, Steven J

(1137-101) A Phase I Trial of CBL0137 in Patients with Advanced Solid Neoplasms

Principal Investigator: Iyer, Renuka V

NY-ESO-1 Expression in Patients with Solid Tumors

Principal Investigator: Odunsi, Adekunle O

Impact of Carbonyl Reductase 3 Genotype Status on Echocardiographic Measurements of Cardiomyopathy in Breast Cancer Patients Treated with Anthracyclines

Principal Investigator: O'Connor, Tracey L

A Phase I/ II Trial of Pazopanib Alternating with Bevacizumab in Treatment-Naive Metastatic Clear Cell Renal Cell Carcinoma Patients

Principal Investigator: George, Saby

Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry

Principal Investigator: Griffiths, Elizabeth A

COG AALL1131, A Phase III Randomized Trial for Newly Diagnosed High Risk BLymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (IND#73789, NSC#732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations

Principal Investigator: Twist, Clare J

(CIBMTR 10-CBA) A Multicenter Access and Distribution Protocol for Unlicensed Cryopreseved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications

Principal Investigator: McCarthy, Philip L

Examining Quality of Life Among Long-Term Survivors of Childhood Cancer

Principal Investigator: Rokitka, Denise A

Mediators of inflammation and injury in patients receiving cancer therapy or allogeneic hematopoietic stem cell transplantation

Principal Investigator: Segal, Brahm

(COG ACNS0831) Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 Years

Principal Investigator: Twist, Clare J

Leukocyte Apheresis for Research

Principal Investigator: Odunsi, Adekunle O

Filgrastim-Mobilized Peripheral Blood Stem Cells for Allogeneic Transplantation with Unrelated Donors (NMDP IRB 1996-005; IRB-1999-0021)

Principal Investigator: McCarthy, Philip L

(COG ALTE03N1) Key Adverse Events After Childhood Cancer

Principal Investigator: Rokitka, Denise A

Lung Bronchoscopy Research Samples & Database

Principal Investigator: Hennon, Mark W

Evaluation and Quality Assurance of the New York State Smokers' Quitline

Principal Investigator: Hyland, Andrew J

Novel Risk Factors and Potential Early Detection Markers for Ovarian Cancer

Principal Investigator: Moysich, Kirsten B

Collection of Blood from Healthy Donors and Patients with Non-Hodgkin's Lymphoma and Leukemia to Study the Immunological Activity of Peripheral Blood Mononuclear Cells (PBMC) and Human Serum

Principal Investigator: Hernandez-Ilizaliturri, Francisco J

(COG ALTE05N1) Umbrella Long-Term Follow-Up Protocol

Principal Investigator: Rokitka, Denise A

Evaluation of Smoker Reactions to Novel Tobacco Products

Principal Investigator: Bansal Travers, Maansi

Available Clinical Trials

Clinical Trials

Patients

Research & Education

Get Involved

Roswell Park

Access